Literature DB >> 22572967

The cost-effectiveness of tiotropium for the treatment of chronic obstructive pulmonary disease (COPD): the importance of the comparator.

Mattias Neyt1, Ann Van Den Bruel.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22572967     DOI: 10.1007/s10198-012-0392-9

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


× No keyword cloud information.
  6 in total

1.  The importance of the comparator in economic evaluations: working on the efficiency frontier.

Authors:  Mattias Neyt; Hans Van Brabandt
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

2.  Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.

Authors:  D D Briggs; H Covelli; R Lapidus; S Bhattycharya; S Kesten; C Cassino
Journal:  Pulm Pharmacol Ther       Date:  2005-04-25       Impact factor: 3.410

3.  Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy.

Authors:  O Zaniolo; S Iannazzo; L Pradelli; M Miravitlles
Journal:  Eur J Health Econ       Date:  2010-11-18

4.  Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis.

Authors:  Ann Van den Bruel; Jeannine Gailly; Mattias Neyt
Journal:  BMC Pulm Med       Date:  2010-09-21       Impact factor: 3.317

5.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.

Authors:  V Brusasco; R Hodder; M Miravitlles; L Korducki; L Towse; S Kesten
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 6.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

Authors:  Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski
Journal:  Am J Respir Crit Care Med       Date:  2007-05-16       Impact factor: 21.405

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.